首页> 美国卫生研究院文献>The Journal of Infectious Diseases >Evaluation of the Antiviral Response to Zanamivir Administered Intravenously for Treatment of Critically Ill Patients With Pandemic Influenza A (H1N1) Infection
【2h】

Evaluation of the Antiviral Response to Zanamivir Administered Intravenously for Treatment of Critically Ill Patients With Pandemic Influenza A (H1N1) Infection

机译:静脉输注扎那米韦抗病毒反应的评估用于治疗重症甲型H1N1流感重症患者

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

A retrospective nationwide study on the use of intravenous (IV) zanamivir in patients receiving intensive care who were pretreated with oseltamivir in the Netherlands was performed. In 6 of 13 patients with a sustained reduction of the viral load, the median time to start IV zanamivir was 9 days (range, 4–11 days) compared with 14 days (range, 6–21 days) in 7 patients without viral load reduction (P = .052). Viral load response did not influence mortality. We conclude that IV zanamivir as late add-on therapy has limited effectiveness. The effect of an immediate start with IV zanamivir monotherapy or in combination with other drugs need to be evaluated.
机译:在荷兰进行了一项回顾性全国性研究,该研究对接受奥塞米韦预处理的重症监护患者使用扎那米韦静脉注射治疗。在13例病毒载量持续降低的患者中,开始进行扎那米韦的中位时间为9天(范围4-11天),而7例无病毒载量的患者开始14天(范围6-21天)减少(P = .052)。病毒负荷反应不影响死亡率。我们得出结论,静脉注射扎那米韦作为晚期附加疗法疗效有限。立即评估IV扎那米韦单药治疗或与其他药物联合使用的效果。

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号